US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Latest News about NASDAQ:IMUX

Recent news which mentions NASDAQ:IMUX

Immunic Inc. CEO Daniel Vitt Highlights Advances in MS Treatment on World MS Day
Tags NASDAQ:IMUX
From News Direct
Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day
Tickers IMUX
Tags NASDAQ:IMUX
From News Direct
Immunic chief medical officer discusses promising treatments to mark World IBD Day
Tickers IMUX
Tags NASDAQ:IMUX
From News Direct
Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day
Tickers IMUX
Tags NASDAQ:IMUX
From News Direct
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
Tickers IMUX
Tags NASDAQ:IMUX
From News Direct
IMUX Stock Earnings: Immunic Misses EPS for Q1 2024
Tickers IMUX
Tags Earnings Reports NASDAQ:IMUX Market News
From InvestorPlace
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
Tickers IMUX
Tags NASDAQ:IMUX
From News Direct
Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role
Tags NASDAQ:IMUX
From News Direct
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
Tickers IMUX
Tags NASDAQ:IMUX
From News Direct
Immunic secures key patent, boosting MS drug exclusivity and global IP strategy
Tags NASDAQ:IMUX
From News Direct
Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024
Tags NASDAQ:IMUX
From News Direct
Immunic reports successful 2023 and prepares for key 2025 milestones
Tags NASDAQ:IMUX
From News Direct
Immunic focusing on business development during Q4
Tags NASDAQ:IMUX
From News Direct
Immunic CSO hails "great" progress with MS program
Tickers IMUX
Tags NASDAQ:IMUX
From News Direct
Immunic "super excited" about latest PMS trial data
Tickers IMUX
Tags NASDAQ:IMUX
From News Direct
Immunic CEO hails "great day" after completing IMU-838 phase 2 trial enrolment
Tickers IMUX
Tags NASDAQ:IMUX
From News Direct
Immunic CEO says Q2 results "couldn't be better"
Tickers IMUX
Tags NASDAQ:IMUX
From News Direct
Immunic Inc eyeing "big step" for multiple sclerosis patients
Tickers IMUX
Tags NASDAQ:IMUX
From News Direct
Immunic Therapeutics shares IMU-856 mode of action and target for gastrointestinal diseases
Tags NASDAQ:IMUX
From News Direct
Immunic ultimately hoping to "offer patients a new kind of treatment" for multiple sclerosis
Tags NASDAQ:IMUX
From News Direct
Immunic says preclinical data for vidofludimus calcium is a milestone for its lead MS program
Tags NASDAQ:IMUX
From News Direct
Immunic Inc set to bring relief with encouraging results
Tickers IMUX
Tags NASDAQ:IMUX
From News Direct
Immunic IMU-856 trial data "clearly goes beyond" initial expectations
Tickers IMUX
Tags NASDAQ:IMUX
From News Direct
Immunic gets a "positive surprise" from lead asset trial
Tickers IMUX
Tags NASDAQ:IMUX
From News Direct
2 Biotech Stocks to Take off Your Watchlist in 2022
Tags NASDAQ:IMUX :DNA
From StockNews.com